Hallmark-Sonali Bank Loan Scam

Knight Therapeutics Reports Third Quarter 2023 Results

Retrieved on: 
Thursday, November 9, 2023

Gross margin: For the quarter ended September 30, 2023, gross margin, as a percentage of revenues, was 49% compared to 42% in Q3-22.

Key Points: 
  • Gross margin: For the quarter ended September 30, 2023, gross margin, as a percentage of revenues, was 49% compared to 42% in Q3-22.
  • Selling and marketing (“S&M”): For the quarter ended September 30, 2023, S&M expenses were $11,924, a decrease of $1,532 or 11%, compared to the same period in prior year.
  • General and administrative (“G&A”): For the quarter ended September 30, 2023, G&A expenses were $11,080, an increase of $664 or 6%, compared to the same period in prior year.
  • For the quarter ended September 30, 2023, interest income was $3,055, an increase of $593 or 24%, compared to the same period in prior year.

Steppe Gold Signs Binding Term Sheet for US$150 Million to Fully Fund the Phase 2 Expansion at the ATO Gold Mine

Retrieved on: 
Wednesday, July 12, 2023

ATO Phase 2 Expansion Highlights:

Key Points: 
  • ATO Phase 2 Expansion Highlights:
    -- US$150 million fully funded to finance the Phase 2 Expansion of the ATO Gold Mine.
  • -- Fresh rock mine expansion life is 12 years, extending open pit mining and milling operations to December 2036.
  • Steppe Gold Chairman and CEO, Mr. Bataa Tumur-Ochir commented, "This is a significant milestone for Steppe Gold and secures the future of the ATO Gold mine for the next 14 years.
  • Goh Way Chuan, Director of TDB Capital commented, "We are delighted to announce the extension of our long-standing partnership with Steppe Gold.

Knight Therapeutics Reports Second Quarter 2023 Results

Retrieved on: 
Thursday, August 10, 2023

Gross margin: For the quarter ended June 30, 2023, gross margin, as a percentage of revenues, was 42% in Q2-23 and 51% Q2-22.

Key Points: 
  • Gross margin: For the quarter ended June 30, 2023, gross margin, as a percentage of revenues, was 42% in Q2-23 and 51% Q2-22.
  • Under the terms of the 2023 NCIB, Knight may purchase for cancellation up to 5,999,524 common shares of the Company which represented 10% of its public float as at June 30, 2023.
  • The increase in the financial outlook is primarily due to an improvement in LATAM currencies against the Canadian dollar in the second quarter of 2023.
  • Knight will host a conference call and audio webcast to discuss its second quarter ended June 30, 2023, today at 8:30 am ET.

Knight Therapeutics Reports First Quarter 2023 Results

Retrieved on: 
Thursday, May 11, 2023

In addition to the full amount of the 2022 MOH Contract of $18,400, subsequent to the quarter, Knight received an order for an additional $9,000 (“2023 MOH Contract”) from the Ministry of Health of Brazil which was delivered in April 2023.

Key Points: 
  • In addition to the full amount of the 2022 MOH Contract of $18,400, subsequent to the quarter, Knight received an order for an additional $9,000 (“2023 MOH Contract”) from the Ministry of Health of Brazil which was delivered in April 2023.
  • Selling and marketing (“S&M”): For the quarter ended March 31, 2023, S&M expenses were $10,665, an increase of $975 or 10% compared to the same period in prior year.
  • Adjusted EBITDA: For the quarter ended March 31, 2023, adjusted EBITDA was $18,237, an increased of $4,925 or 37%.
  • Net loss: For the quarter ended March 31, 2023, net loss was $3,937 compared to net loss of $18,811 for the same period in prior year.

Knight Therapeutics Reports Fourth Quarter and Year-End 2022 Results

Retrieved on: 
Thursday, March 23, 2023

Selling and marketing: For the quarter ended December 31, 2022, S&M increased by $2,111 or 17%.

Key Points: 
  • Selling and marketing: For the quarter ended December 31, 2022, S&M increased by $2,111 or 17%.
  • General and administrative: For the quarter ended on December 31, 2022, there was no significant variation in General and administrative expenses.
  • Research and development expenses: For the quarter ended on December 31, 2022, there was no significant variation in Research and development expenses.
  • In addition, during the fourth quarter of 2022, Knight also submitted a branded generic of for regulatory approval in Chile and Colombia.

Pretium Congratulates Roberta Goss for Recognition as One of The Most Notable Women on Wall Street by Crain's New York Business

Retrieved on: 
Thursday, December 1, 2022

Award recipients are selected by the Crain's New York editorial team and recognize influential women who have made a positive impact on the New York City financial sector.

Key Points: 
  • Award recipients are selected by the Crain's New York editorial team and recognize influential women who have made a positive impact on the New York City financial sector.
  • In her three years since joining Pretium, Ms. Goss has played an instrumental role leading the development of the firm's Crown Point collateralized loan obligation (CLO) business and managing investments across its other leveraged loan portfolios.
  • To read more about Ms. Goss' recognition, please visit the Crain's New York Business website .
  • Pretium is a specialized investment firm focused on U.S. residential real estate, residential credit, and corporate credit.

Gen II Fund Services Appoints Michael Abatemarco as Head of Credit

Retrieved on: 
Tuesday, August 9, 2022

Gen II Fund Services, LLC (Gen II), a leading independent private capital fund administrator, today announced Michael Abatemarco will join the firm as Head of Credit, effective August 9.

Key Points: 
  • Gen II Fund Services, LLC (Gen II), a leading independent private capital fund administrator, today announced Michael Abatemarco will join the firm as Head of Credit, effective August 9.
  • At Gen II, he will lead the credit fund administration and credit middle office services business, which provides private credit fund clients with an end-to-end service model.
  • With his extensive expertise in credit fund operations, we believe Michael will be a strong addition to the Gen II team, said Steven Millner, CEO of Gen II.
  • We are confident that with Michael as Head of Credit, Gen II is well positioned to continue providing our clients with market-leading private credit capabilities.

Knight Therapeutics Reports First Quarter 2022 Results

Retrieved on: 
Thursday, May 12, 2022

Amortization of intangible assets: For the quarter ended March 31, 2022, amortization of intangible assets increased by $5,986 due to the acquisition of Exelon.

Key Points: 
  • Amortization of intangible assets: For the quarter ended March 31, 2022, amortization of intangible assets increased by $5,986 due to the acquisition of Exelon.
  • Adjusted EBITDA: For the quarter ended March 31, 2022, adjusted EBITDA increased by $7,732 or 139%.
  • Net loss or income: For the quarter ended March 31, 2022, net loss was $18,811 compared to net income of $3,558 for the same period in prior year.
  • Knight obtained regulatory approval and launched Lenvima, Halaven and Rembre in Colombia during the first quarter of 2022.

Hartford Funds Launches Its First Sustainable Investing-Focused Fixed Income ETF

Retrieved on: 
Wednesday, September 22, 2021

Hartford Funds today announced the launch of an actively managed, ESG-focused fixed income exchange-traded fund (ETF), Hartford Sustainable Income ETF (CBOE: HSUN), which will be sub-advised by Wellington Management Company LLP.

Key Points: 
  • Hartford Funds today announced the launch of an actively managed, ESG-focused fixed income exchange-traded fund (ETF), Hartford Sustainable Income ETF (CBOE: HSUN), which will be sub-advised by Wellington Management Company LLP.
  • We are excited to launch a multi-sector bond fund that uses a sustainable investing approach in an ETF structure, said Vernon Meyer, Chief Investment Officer at Hartford Funds.
  • HSUN is listed on Cboe BZX Exchange, Inc.
    For more information about the Hartford Sustainable Income ETF, please visit hartfordfunds.com.
  • Founded in 1996, Hartford Funds is a leading asset manager, which provides mutual funds, ETFs, and 529 college savings plans.